BIOMAT Database Logo BIOMAT Database Logo

[Clinical significance of proliferating cell nuclear antigen (PCNA) and argyrophilic nucleolar organizer region (AgNOR) in testicular tumors]. 1995

C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
Department of Urology, Tohoku University School of Medicine.

BACKGROUND Proliferative potential of testicular tumor was assessed by immunohistochemistry using anti-proliferating cell nuclear antigen (PCNA) monoclonal antibody and silver staining of argyrophilic nucleolar organizer region (AgNOR), and the results were compared with clinical course. METHODS Fourty-five patients with testicular tumor and 10 normal testicles were investigated. All specimens were fixed with 10% buffered formaliun within 24 hours. The interval between patient's recognition of testicular swelling for the first time and the date for operation was designated as M (months), and the specimen weight was designated as g (gram). Growth rate of the primary tumor was estimated roughly by g/M. RESULTS PCNA positive rates in seminomas, non-seminomas and normal testes were 70.5 +/- 19.1% (mean +/- S.D.), 80.4 +/- 10.5% and 17.7 +/- 7.8%, respectively. PCNA positive rate in stage I seminoma (64.4 +/- 19.9%) was significantly lower than stage II and III seminoma (83.6 +/- 7.3%) (p < 0.05), but not significant between stage I non-seminoma and stage II, III non-seminoma. The mean numbers of AgNOR per nucleus in seminomas, non-seminomas and normal testes were 8.09 +/- 1.35 (mean +/- S.D.), 6.89 +/- 1.43, 4.18 +/- 1.60, respectively and significantly higher in testicular tumors than normal testes. There were, however, no significant difference between their clinical stages. Logarithmic significant correlation was observed between PCNA positive rate and the growth rate in primary lesion, but no correlation was found between mean number of AgNOR per nuclei and the growth rate. Of the 10 patients with stage I non-seminomas received surveillance policy, four relapsed. Of the 10 patients, 4 of the 6 patients with higher than 75% PCNA positive rate relapsed, whereas, none of the 4 patients with lower than 75% PCNA positive rate relapsed. There were no significant correlation between PCNA positive rate and number of AgNOR. CONCLUSIONS PCNA is more accurate indicator of growth potential in testicular tumor than AgNOR and may predict recurrence in stage I non-seminomatous testicular tumor patients followed by surveillance policy.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D009697 Nucleolus Organizer Region The chromosome region which is active in nucleolus formation and which functions in the synthesis of ribosomal RNA. Nucleolar Organizer,Nucleolar Organizers,Nucleolus Organizer Regions,Organizer Region, Nucleolus,Organizer Regions, Nucleolus,Organizer, Nucleolar,Organizers, Nucleolar,Region, Nucleolus Organizer,Regions, Nucleolus Organizer
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013724 Teratoma A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642) Dysembryoma,Teratoid Tumor,Teratoma, Cystic,Teratoma, Mature,Teratoma, Benign,Teratoma, Immature,Teratoma, Malignant,Benign Teratoma,Benign Teratomas,Dysembryomas,Immature Teratoma,Immature Teratomas,Malignant Teratoma,Malignant Teratomas,Teratoid Tumors,Teratomas,Teratomas, Benign,Teratomas, Immature,Teratomas, Malignant,Tumor, Teratoid,Tumors, Teratoid
D013736 Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms. Cancer of Testis,Cancer of the Testes,Testicular Cancer,Testicular Neoplasm,Testicular Tumor,Testis Cancer,Cancer of the Testis,Neoplasms, Testicular,Neoplasms, Testis,Testicular Tumors,Testis Neoplasms,Tumor of Rete Testis,Cancer, Testicular,Cancer, Testis,Cancers, Testicular,Cancers, Testis,Neoplasm, Testicular,Neoplasm, Testis,Rete Testis Tumor,Rete Testis Tumors,Testicular Cancers,Testis Cancers,Testis Neoplasm,Testis Tumor, Rete,Testis Tumors, Rete,Tumor, Testicular,Tumors, Testicular
D016622 Silver Staining The use of silver, usually silver nitrate, as a reagent for producing contrast or coloration in tissue specimens. Silver Nitrate Staining,Nitrate Staining, Silver,Staining, Silver,Staining, Silver Nitrate
D018236 Carcinoma, Embryonal A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595) Carcinomas, Embryonal,Embryonal Carcinoma,Embryonal Carcinomas

Related Publications

C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
[Analysis of proliferating cell nuclear antigen and nucleolar organizer region in testicular tumors].
August 1993, Hinyokika kiyo. Acta urologica Japonica,
C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
Evaluation of argyrophilic nucleolar organizer region and proliferating cell nuclear antigen in colorectal cancer.
September 1998, Journal of surgical oncology,
C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
The prognostic significance of the cytophotometric DNA content and its relationship with the argyrophilic nucleolar organizer regions (AgNOR) and proliferating cell nuclear antigen (PCNA) in oesophageal cancer.
August 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumours.
February 1992, The Journal of pathology,
C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma.
June 2001, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma.
January 1995, Pathology,
C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
Proliferating cell nuclear antigen and argyrophilic nucleolar organizer regions in patients with thymic disease.
January 1997, Oncology reports,
C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
June 1996, Experimental hematology,
C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
[Argyrophilic nucleolar organizer region (AgNOR) in gastric cancer: preliminary report].
January 1992, Nihon Geka Gakkai zasshi,
C Ohyama, and A Ito, and S Tokuyama, and H Nakazumi, and K Suzuki, and S Kawamura, and M Sato, and S Saito, and K Yoshikawa, and S Hoshi
Prognostic significance of argyrophilic nucleolar organizer region (AgNOR) in resected non-small cell lung cancer (NSCLC).
October 1997, Japanese journal of clinical oncology,
Copied contents to your clipboard!